scholarly journals Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum  -lactamase-producing Escherichia coli using an in vitro model

2008 ◽  
Vol 61 (3) ◽  
pp. 643-646 ◽  
Author(s):  
G. G. Zhanel ◽  
P. Baudry ◽  
V. Vashisht ◽  
N. Laing ◽  
A. M. Noreddin ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
In Vitro Model ◽  
Multidrug Resistant ◽  
Extended Spectrum ◽  
Vitro Model

scholarly journals An in vitro model of catheter-associated urinary tract infections to investigate the role of uncommon bacteria on the Escherichia coli microbial consortium

2017 ◽  
Vol 118 ◽  
pp. 64-69 ◽  
Author(s):  
Andreia S. Azevedo ◽  
Carina Almeida ◽  
Luciana C. Gomes ◽  
Carla Ferreira ◽  
Filipe J. Mergulhão ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
In Vitro Model ◽  
Microbial Consortium ◽  
Vitro Model ◽  
Tract Infections

scholarly journals Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.

1996 ◽  
Vol 40 (3) ◽  
pp. 734-738 ◽  
Author(s):  
A A Firsov ◽  
D Saverino ◽  
D Savarino ◽  
M Ruble ◽  
D Gilbert ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
In Vitro Model ◽  
Dynamic Models ◽  
Beta Lactamase ◽  
Beta Lactam ◽  
Time Curve ◽  
Peripheral Tissues ◽  
Vitro Model

The clinical outcome in patients treated with ampicillin-sulbactam may not always be predictable by disc susceptibility testing or with the MIC as determined with a constant level (4 micrograms/ml) of the beta-lactamase inhibitor (MIC1). The enzyme activities (EA) and the MICs estimated at a constant ratio of ampicillin to sulbactam of 2:1 (MIC2) for 15 TEM-1 beta-lactamase-producing strains of Escherichia coli were examined as alternatives to MIC1 as predictors of the antibacterial effects of this combined drug as studied in an in vitro model which simulates ampicillin-sulbactam pharmacokinetic profiles observed in human peripheral tissues. Integral parameters describing the area under the bacterial count-time curve (AUBC), the area between the normal growth curve, and the killing curve of bacteria exposed to antibiotic (ABBC), and the second parameter expressed as a percentage of its maximal hypothetical value (ABBC/ABBCmax) were calculated. All three parameters correlated well with EA (AUBC, r = 0.93; ABBC, r = -0.88; ABBC/ABBCmax, r = -0.91) and with MIC2 (r = 0.94, -0.94, and -0.95, respectively) but not with MIC1. Both EA and MIC2 can be considered reliable predictors of the antibacterial effect of ampicillin-sulbactam in an in vitro model. These correlations suggest that in vitro kinetic-dynamic models might be useful to reexamine established susceptibility breakpoints obtained with data based on the MIC1 (MICs obtained with constant levels of beta-lactamase inhibitors). These data also suggest that quantitative determinations of bacterial beta-lactamase production and MICs based on the component concentration ratio observed in vivo might be useful predictors of the effect of ampicillin-sulbactam and other beta-lactam-inhibitor combinations.

scholarly journals In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

2018 ◽  
Vol 63 (1) ◽  
Author(s):  
James A. Karlowsky ◽  
Heather J. Adam ◽  
Melanie R. Baxter ◽  
Andrew J. Denisuik ◽  
Philippe R. S. Lagacé-Wiens ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Multidrug Resistant ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Broth Microdilution ◽  
Content Type ◽  
Extended Spectrum ◽  
Urinary Isolates

ABSTRACT The in vitro activity of sulopenem was assessed against a collection from 2014 to 2016 of 539 urinary isolates of Escherichia coli from Canadian patients by using CLSI-defined broth microdilution methodology. A concentration of sulopenem 0.03 µg/ml inhibited both 50% (MIC50) and 90% (MIC90) of isolates tested; sulopenem MICs ranged from 0.015 to 0.25 µg/ml. The in vitro activity of sulopenem was unaffected by nonsusceptibility to trimethoprim-sulfamethoxazole and/or ciprofloxacin, multidrug-resistant phenotypes, extended-spectrum β-lactamases, or AmpC β-lactamases.

scholarly journals ISEcp1-Mediated Transposition of qnrB-Like Gene in Escherichia coli

2008 ◽  
Vol 52 (8) ◽  
pp. 2929-2932 ◽  
Author(s):  
Vincent Cattoir ◽  
Patrice Nordmann ◽  
Jesus Silva-Sanchez ◽  
Paula Espinal ◽  
Laurent Poirel
Keyword(s):  
Escherichia Coli ◽  
Clinical Isolate ◽  
In Vitro Model ◽  
Resistance Determinant ◽  
Insertion Element ◽  
Its Gene ◽  
Vitro Model

ABSTRACT A novel QnrB-like plasmid-mediated resistance determinant, QnrB19, was identified from an Escherichia coli clinical isolate from Colombia. Its gene was associated with an ISEcp1-like insertion element that did not act as a promoter for its expression. Using an in vitro model of transposition, we showed that the ISEcp1-like element was able to mobilize the qnrB19 gene.

Sign in / Sign up

Export Citation Format

Share Document